Table 3.
Factors determining event free survival, progression free survival and overall survival
| Variables | EFS (n) | Estimated percentages of EFS at 4 years (%) | p value | PFS (n) | Estimated percentages of PFS at 4 years (%) | p value | OS (n) | Estimated percentages of OS at 4 years (%) | p value |
|---|---|---|---|---|---|---|---|---|---|
| Allo-SCT versus chemotherapy only group | 0.21 | 0.02 | 0.15 | ||||||
| Allo-SCT | 09/16 | 36 ± 17.9 | 09/10 | 75 ± 21.7 | 09/16 | 36.4 ± 18.1 | |||
| Chemotherapy only | 10/30 | 27.3 ± 9.1 | 10/24 | 34.1 ± 10.9 | 24/30 | 53.4 ± 17.8 | |||
| Age | 0.96 | 0.58 | 0.49 | ||||||
| ≤ 40 years | 11/28 | 30.3 ± 10.5 | 11/21 | 45.4 ± 12.4 | 19/28 | 44.4 ± 14.2 | |||
| > 40 years | 08/18 | 33.7 ± 13.8 | 08/13 | 46.6 ± 17.8 | 14/18 | 54.6 ± 23.2 | |||
| WBC count | 0.90 | 0.50 | 0.59 | ||||||
| ≤ 1,00,000/cumm | 16/34 | 41.2 ± 9.6 | 16/25 | 57.1 ± 11.7 | 26/34 | 63.2 ± 11.7 | |||
| > 1,00,000/cumm | 03/12 | 20.8 ± 12.6 | 03/09 | 29.6 ± 16.4 | 07/12 | 25.8 ± 20.5 | |||
| CNS disease | 0.55 | 0.34 | 0.28 | ||||||
| CNS-1 | 17/41 | 31.8 ± 8.7 | 17/30 | 45.9 ± 11 | 28/41 | 44 ± 13.2 | |||
| CNS-3 | 02/05 | 40 ± 21.9 | 02/04 | 50 ± 25 | 05/05 | 100 | |||
| Pre consolidation MMR | 0.93 | 0.84 | 0.33 | ||||||
| ≤ 0.1% | 12/30 | 35.3 ± 9.4 | 12/23 | 46.6 + 11.4 | 23/30 | 61.1 ± 12.3 | |||
| > 0.1% | 07/16 | 18.2 ± 15.5 | 07/11 | 35.1 ± 25.9 | 10/16 | 24.6 ± 20.4 | |||
| Cytogenetics | 0.60 | 0.67 | 0.35 | ||||||
| Without additional cytogenetics | 07/22 | 20.8 ± 10.1 | 07/14 | 35.7 ± 15.3 | 13/22 | 30 ± 15.7 | |||
| With additional cytogenetics | 07/15 | 40 ± 15.1 | 07/11 | 54.5 ± 18.7 | 12/15 | 64.3 ± 19.8 |
Statistically significant value in bold